BONE: STAR (Switching to TAF Based Anti-Retroviral Therapy) Study
Status:
Recruiting
Trial end date:
2023-06-06
Target enrollment:
Participant gender:
Summary
The primarily objective of this study is to assess the effect of switching from Tenofovir
Disoproxil Fumurate (TDF) to TAF based ART on bone mass and turnover among women on DMPA for
contraception. HIV virologically suppressed women on DMPA will be switched from their TDF
based regimen to Bictergravir /Emtricitabine / Tenofovir alafenamide (B/F/TAF; Biktarvy®) in
a randomized fashion. HIV infected women on TDF and non-hormonal contraception will be
switched to Biktarvy®).